- Home
- BCTXZ vs SE Comparison
BCTXZ vs SE Comparison
Compare BCTXZ & SE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTXZ
- SE
- Stock Information
- Founded
- BCTXZ N/A
- SE 2009
- Country
- BCTXZ Canada
- SE Singapore
- Employees
- BCTXZ 12
- SE N/A
- Industry
- BCTXZ
- SE Other Consumer Services
- Sector
- BCTXZ
- SE Consumer Discretionary
- Exchange
- BCTXZ Nasdaq
- SE Nasdaq
- Market Cap
- BCTXZ N/A
- SE N/A
- IPO Year
- BCTXZ N/A
- SE 2017
- Fundamental
- Price
- BCTXZ $0.94
- SE $139.17
- Analyst Decision
- BCTXZ
- SE Buy
- Analyst Count
- BCTXZ 0
- SE 13
- Target Price
- BCTXZ N/A
- SE $124.92
- AVG Volume (30 Days)
- BCTXZ N/A
- SE 3.8M
- Earning Date
- BCTXZ N/A
- SE 05-13-2025
- Dividend Yield
- BCTXZ N/A
- SE N/A
- EPS Growth
- BCTXZ N/A
- SE 196.00
- EPS
- BCTXZ N/A
- SE 0.74
- Revenue
- BCTXZ N/A
- SE $16,819,866,000.00
- Revenue This Year
- BCTXZ N/A
- SE $29.44
- Revenue Next Year
- BCTXZ N/A
- SE $19.05
- P/E Ratio
- BCTXZ N/A
- SE $187.55
- Revenue Growth
- BCTXZ N/A
- SE 28.75
- 52 Week Low
- BCTXZ N/A
- SE $55.00
- 52 Week High
- BCTXZ N/A
- SE $147.73
- Technical
- Relative Strength Index (RSI)
- BCTXZ N/A
- SE 59.90
- Support Level
- BCTXZ N/A
- SE $139.80
- Resistance Level
- BCTXZ N/A
- SE $147.14
- Average True Range (ATR)
- BCTXZ 0.00
- SE 4.15
- MACD
- BCTXZ 0.00
- SE 1.73
- Stochastic Oscillator
- BCTXZ 0.00
- SE 73.96
About BCTXZ BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.